Receiving Mature Dendritic Cells in Vitro in Patients with Tumors of Different Localization

Event Abstract Back to Event Receiving mature dendritic cells in vitro in patients with tumors of different localization Vasily Kurilin1*, Irina Obleuhova1, Ekaterina Kulikova1, Julia Khantakova1, Julia Shevcenko1, Vladimir Yakushenko2, Andrey Sokolov3, Andrey Sokolov3, Sergey Sidorov3 and Sergey Sennikov1 1 Federal State Budgetary Institution "Research Institute of Clinical Immunology" under the Russian Academy of Medical Sciences Siberian Branch, Russia 2 Hospital №11, Russia 3 Hospital №1, Russia In this study we used peripheral venous blood of patients with epithelial tumors of different localization (gaster, lung, colon, ovary). MNCs were isolated from peripheral blood on gradient. Then isolated monocytes by adhesion on plastic, followed by culturing for 48h in the presence GM-CSF (50 ng/ml), IL-4 (100ng/ml) and for 24h in presence TNF-α (25ng/ml) [1]. Maturation of DCs was assessed by flow cytometry on the expression of maturation markers (CD83, CD86, CD11c, HLA-DR) on cells and capture FITC-dextran. The protocol used cultivation DC with mature phenotype (high expression of CD83, CD86, CD11c, HLA-DR, low endocytic activity), which was shown in experiments in vitro on cells conditionally healthy donors. This protocol is used to assess the ability of cancer patients to MNCs maturation and differentiation into mature DCs. It was shown that in the culture of patients with epithelial ovarian cancer and colorectal cancer is significantly increased expression of CD83, HLA-DR, CD86, and decreased endocytic activity, which may indicate the ability of intact cell precursors of dendritic cells (monocytes) to differentiate into mature forms of DC [2]. In patients with gastric cancer or lung when cultured DCs was no significant increase of maturation markers and changes in endocytic activity, which points to a violation of differentiation and maturation of dendritic cells in cancer of the stomach and lung. Thus, in the used cellular protocol has been shown that the various types of cancer can vary the capacity for maturation of dendritic cells in vitro conditions in the presence of IL-4, GM-CSF, TNFa. Acknowledgements The study was supported by The Ministry of education and science of Russian Federation, project 8265 and 8790. References 1. Obermaier B., Dauer M., Herten J., Schad K., Endres S., Eigler A. Development of a new protocol for 2–day generation of mature dendritic cells from human monocytes. // Biol. Proced. Online.- 2003.- Vol.5.- P.197-203. 2. Nersting J., Svenson M., Andersen V., Bendtzen K. Maturation of human dendritic cells by monocyte–conditioned medium is dependent upon trace amounts of lipopolysaccharide inducing tumour necrosis factor a // Immunology Letters.- 2003.- Vol.89.- P.59–65. Keywords: Dendritic Cells, Cancer, cultivation, IL-4, GM-CSF, TNFa Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013. Presentation Type: Abstract Topic: Adaptive Immunity Citation: Kurilin V, Obleuhova I, Kulikova E, Khantakova J, Shevcenko J, Yakushenko V, Sokolov A, Sokolov A, Sidorov S and Sennikov S (2013). Receiving mature dendritic cells in vitro in patients with tumors of different localization. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00116 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 11 Mar 2013; Published Online: 22 Aug 2013. * Correspondence: Dr. Vasily Kurilin, Federal State Budgetary Institution "Research Institute of Clinical Immunology" under the Russian Academy of Medical Sciences Siberian Branch, Novosibirsk, Russia, 2221910@ngs.ru Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Vasily Kurilin Irina Obleuhova Ekaterina Kulikova Julia Khantakova Julia Shevcenko Vladimir Yakushenko Andrey Sokolov Andrey Sokolov Sergey Sidorov Sergey Sennikov Google Vasily Kurilin Irina Obleuhova Ekaterina Kulikova Julia Khantakova Julia Shevcenko Vladimir Yakushenko Andrey Sokolov Andrey Sokolov Sergey Sidorov Sergey Sennikov Google Scholar Vasily Kurilin Irina Obleuhova Ekaterina Kulikova Julia Khantakova Julia Shevcenko Vladimir Yakushenko Andrey Sokolov Andrey Sokolov Sergey Sidorov Sergey Sennikov PubMed Vasily Kurilin Irina Obleuhova Ekaterina Kulikova Julia Khantakova Julia Shevcenko Vladimir Yakushenko Andrey Sokolov Andrey Sokolov Sergey Sidorov Sergey Sennikov Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.